WO2011050728A1 - 一种稳定的雷沙吉兰组合物 - Google Patents
一种稳定的雷沙吉兰组合物 Download PDFInfo
- Publication number
- WO2011050728A1 WO2011050728A1 PCT/CN2010/078189 CN2010078189W WO2011050728A1 WO 2011050728 A1 WO2011050728 A1 WO 2011050728A1 CN 2010078189 W CN2010078189 W CN 2010078189W WO 2011050728 A1 WO2011050728 A1 WO 2011050728A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- rasagiline
- antioxidant
- polymer
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Definitions
- the present invention relates to the field of pharmaceutical preparations, and in particular to a stable rasagiline composition containing an effective amount of rasagiline or a pharmaceutically acceptable salt thereof and as Stabilizer antioxidant.
- the composition is for treating or preventing a mental system disorder.
- BACKGROUND OF THE INVENTION Rasagiline is an irreversible selective monoamine oxidase B (MAOB) inhibitor that can be used to treat or prevent Parkinson's disease, Alzheimer's disease, depression, ADHD, restless legs syndrome, multiple Sexual sclerosis and withdrawal syndrome.
- MAOB selective monoamine oxidase B
- the molecular formula of rasagiline is shown below:
- transdermal and mucosal administration include patches, cataplasms, gels, ointments, creams, films, sprays, and solutions. These dosage forms are used for transdermal and mucosal administration, each having its own characteristics: The patch and the cataplasm can be attached to the skin relatively firmly, so that the drug can be slowly and permanently released and absorbed, and the medicine is convenient and does not pollute the clothes.
- a rasagiline transdermal patch for treating or preventing a neurological disorder is disclosed in Chinese patent application CN101032474A, which comprises an inert support layer that does not chemically interact with the matrix component, one containing a ray a matrix layer of sagelan or a pharmaceutically acceptable salt thereof and a protective layer to be removed before use.
- the matrix layer is a drug-loading reservoir containing an organic high molecular polymer material and an inorganic or organic material as a regulator.
- the reservoir contains rasagiline; the matrix also contains one or more substances that promote transdermal absorption of rasagiline.
- the pH of the patch is maintained in the alkaline range (greater than 7.0). Although a good transdermal permeation effect can be obtained, the study finds that under the high temperature stability test condition, the drug stability is not good, which may be disadvantageous for long-term. Store.
- a stable controlled release rasagiline transdermal patch is disclosed in Chinese Patent Application No. CN200810069850.1 (Publication No.
- CN101606923A which comprises: a) an effective amount of rasagiline and a pharmaceutically acceptable salt thereof, b) at least one hydrophilic polymer matrix, c) a pH of the patch of not more than 7.0, preferably a pH of not less than 3.0 to not more than 6.5.
- the patch maintains the stability and good transdermal effect of rasagiline, it is suitable for long-term storage and is less irritating to the skin, but it is attached to the skin due to its more hydrophilic polymer matrix. It is not resistant to sweat and is easy to fall off. If the patch is prepared by using a matrix combined with a non-hydrophilic polymer, the preparation steps are cumbersome, the matrix material is selected harshly, and the production cost is high.
- One aspect of the present invention provides a stable rasagiline composition comprising rasagiline or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable antioxidant.
- the composition is stable under high temperature stability test conditions (60 ° C, 10 days), and the stability is good. If it is a patch, the substrate selection conditions are not harsh, easy to obtain, and it is applied to the skin firmly and should not fall off.
- the composition according to the invention wherein the rasagiline or a pharmaceutically acceptable salt thereof is present in an amount of from 0.1% to 40%, based on the total weight of the composition.
- the pharmaceutically acceptable salt of rasagiline comprises a hydrochloride, an oxime sulfonate, an ethanesulfonate or a sulfate.
- the free base form of rasagiline is preferably employed.
- the antioxidant may be any suitable pharmaceutically acceptable antioxidant, for example, one or more selected from the group consisting of tocopherol or an ester thereof.
- the formulation is in the form of a transdermal formulation or a mucosal formulation.
- the transdermal formulation is a transdermal patch, a cataplasm, an emulsion, a cream, a spray or a gel, preferably a transdermal patch.
- Said mucosal administration preparation is Membrane or spray.
- the composition further comprises one or more of the following excipients (carriers): polyacrylic polymer, silicone polymer, polyvinyl alcohol polymer, a polyvinylpyrrolidone polymer, an ethylene vinyl acetate copolymer, a cellulose polymer, a polyethylene glycol polymer, a carbomer polymer, a polyoxyethylene polymer, gelatin, alginic acid or a salt thereof, West gum, gum arabic, silicone oil, water, ethanol, acetone, propanol, propylene glycol, glycerin, ethyl acetate, cetyl alcohol, stearyl alcohol, stearic acid, paraffin wax, beeswa
- excipients carriers
- a transdermal patch may be selected from a polymer or a polymer material such as a polyacrylic polymer or a silicone polymer in the above-mentioned excipients, and a suitable solvent such as ethyl acetate or the like may be selected, such as CN101032474A (2007) These are disclosed in the September 12th, the entire disclosure of which is incorporated herein by reference.
- the transdermal formulation further comprises a transdermal enhancer in addition to the antioxidants and excipients (carriers) described above.
- the transdermal enhancer is one or more of azone, isopropyl myristate, oleic acid, and menthol.
- rasagiline may be present in any type of carrier known in the art.
- One of the uses of the carrier is to form a drug into a patch, a cataplasm, a cream, a gel, etc.
- the rasagiline can be any one of a salt, a free base, a microcrystal, an amorphous, a microemulsion, etc.
- the carrier may contain one or more polymers, and for the patch, a polyacrylic polymer, a silicone polymer; a gel, an ointment, Cream, film, cataplasm, solution, preferably polyacrylic polymer, polyvinyl alcohol polymer, polyvinylpyrrolidone polymer, ethylene vinyl acetate copolymer, cellulose polymer, polyethylene Alcohol polymers, carbomer polymers, polyoxyethylene polymers, gelatin, alginic acid and its salts, tragacanth, gum arabic, silicone oil, and the like.
- the carrier may contain one or more small molecule compounds such as water, ethanol, acetone, propanol, propylene glycol, glycerin, ethyl acetate, medium chain and long chain fat.
- Family (C4 ⁇ 24) such as cetearyl alcohol, stearic acid, paraffin wax, beeswax, lanolin compound, magnesium aluminum silicate, kaolin, titanium dioxide, zinc oxide, aluminum hydroxide, aluminum chloride, tannic acid , tartaric acid, ethylenediaminetetraacetic acid (EDTA), and the like.
- the composition may also contain a skin penetration enhancer such as azone, isopropyl myristate, oleic acid, menthol.
- a skin penetration enhancer such as azone, isopropyl myristate, oleic acid, menthol.
- the methods of making the various formulations involved in the compositions of the present invention can be accomplished using conventional manufacturing techniques of the relevant formulations of the art, such as those described in CN101032474A.
- the composition of the present invention exhibits an odd stability after the addition of the antioxidant, especially when the composition is a transdermal patch, not only is rasagiline very stable, but also sticks to the skin and is not easy to fall off, and the transdermal effect is good.
- the matrix material is easy to obtain, easy to operate, and suitable for industrial production.
- Another aspect of the invention provides a composition according to any of the foregoing for use in the preparation of a treatment Or use in medicines that prevent mental illness.
- the stabilized rasagiline pharmaceutical composition of the present invention is used for treating or preventing treatment of the god system, such as Parkinson's disease, Alzheimer's disease, depression, ADHD, restless legs syndrome, multiple sclerosis And withdrawal syndrome and so on.
- the dosage is to ensure that the blood concentration passed through reaches the effective therapeutic amount (effective blood concentration), which can be once a day, or once every 2-3 days, or once a week.
- the embodiments of the present invention are intended to further illustrate or understand the present invention, but do not limit the scope of the present invention.
- Example 1 Transdermal patch containing rasagiline and antioxidant tocopherol
- Table 1 Composition of a composition containing a transdermal patch of rasagiline and an antioxidant tocopherol
- the rasagiline (free base), polymer and/or antioxidant in the above table is added to ethyl acetate and mixed to obtain a viscous matrix, which is coated on a transparent PET film of 75 ⁇ .
- a 0.2 mm thick film is formed on the layer (protective layer), and after drying at 60 ° C for 5 minutes, the polyethylene backing layer is covered, and then transferred, and then the patch is die cut or cut into the final. Thin slices. Remove the protective layer before applying it to the skin.
- the so-called "related substances” refer to impurities that may be caused by decomposition of rasagiline composition during preparation or storage. It may have adverse effects on the human body and need to be controlled. It is often not a single impurity.
- test solution Take the appropriate amount of the sample containing rasagiline 20mg, tear off the protective layer, place in a 50ml volumetric flask, add 0.1ml / L sterol hydrochloride solution 25ml, Ultrasonic for 30 minutes, let cool, dilute to the mark with mobile phase, shake well, centrifuge (4000 rpm) for 10 minutes, take the supernatant as the test solution;
- control solution Precision measurement Test sample solution 1.0ml, placed in a 100ml volumetric flask, dilute to the mark with mobile phase, shake well, as a control solution;
- Determination method Precision measurement of the test solution and the control solution 20 ⁇ 1, respectively, into the liquid chromatography Instrument, record the chromatogram, calculate the relevant substance according
- the composition of the present invention provides a system which is relatively stable at a high temperature. After the composition of the composition 1-1 to 1-4 of Example 1 is stored in a 60 ° C environment for 10 days, the content of the relevant substance is measured, and the results are shown in the table. 3. The results showed that the content of the relevant substance of the patch to which the antioxidant was added was still less than 5% after storage, and the content of the related substance of the patch without the antioxidant was more than 5%. Table 3: Contents of related substances in the composition of Example 1
- Example 3 CN101606923A Embodiment 4 with 3 displacements greater than 5 mm
- the patch in the first embodiment of the present invention can maintain sufficient adhesion without falling off or shifting, and the patch prepared according to Examples 3, 4, 5, and 6 of CN101606923A is attached to the human body. After 3 days of skin on the chest, there was a shedding or displacement phenomenon. Further, according to the patches prepared in Examples 1 and 2 of CN101606923A, since rasagiline and sulfonic acid form an oxime sulfonate, the solubility in the non-hydrophilic material is small, the drug loading is small, and The cumulative amount of permeation is significantly lower compared to the system provided by the present invention.
- Example 2 Transdermal patch containing rasagiline and the antioxidant butyl hydroxy benzene.
- Table 5 Composition of a composition containing a transdermal patch of rasagiline and an antioxidant butyl hydroxy benzene
- Preparation method The main drug and the polymer and/or antioxidant in the prescription are added to the solvent ethyl acetate and mixed to obtain a viscous matrix, and the substrate is coated on a 75 um transparent PET thin layer (protective layer). A 0.2 mm thick film, after drying at 60 ° C for 5 minutes, is covered with a polyethylene backing layer and transferred, and the patch is die cut or cut into the final sheet. Remove the protective layer before applying it to the skin.
- the compositions of the present invention provide a drug delivery system (patch) that is relatively stable at elevated temperatures. in
- Example 3 Transdermal patch containing rasagiline and the antioxidant ascorbyl palmitate
- Table 7 Composition of a composition containing a transdermal patch of rasagiline and the antioxidant ascorbyl palmitate
- Preparation method rasagiline (free base) and polymer and / or antioxidant are added to ethyl acetate and mixed to obtain a viscous matrix, which is coated on a 75 um transparent PET thin layer (protective layer A 0.2 mm thick film was formed thereon, and after drying at 60 ° C for 5 minutes, a polyethylene backing layer was applied to transfer, and the patch was die cut or cut into a final sheet. Remove the protective layer before applying it to the skin.
- the compositions of the present invention provide a drug delivery system that is relatively stable at elevated temperatures.
- Example 4 Transdermal gel containing rasagiline and antioxidant tocopherol
- Table 9 Composition of a composition containing a transdermal gel of rasagiline and an antioxidant tocopherol
- Preparation method rasagiline and polymer and/or antioxidant are added to ethanol and water, stirred, and the gel is obtained after the polymer is completely swollen, filled in the ointment tube, and sealed. Compared with the patch, the preparation process of the gel is simpler, and an appropriate amount of gel is extruded from the ointment tube and applied to the skin.
- the composition of the present invention provides a system which is relatively stable at high temperatures, and after 10 days of storage in an environment of 60 ° C, the composition of the composition of the present invention is found to have a composition of less than 5% without an antioxidant. The relevant substances are more than 5%, and the results are shown in Table 10 below. Table 10: Content of related substances in the composition of Example 4
- Example 5 Transdermal gel containing rasagiline and butyl hydroxazone
- Table 11 Formulation of a composition containing a transdermal gel of rasagiline and butyl hydroxazone
- Preparation method rasagiline and polymer and / or antioxidant will be added to ethanol and water, stirred, until the polymer is completely swollen, the gel is obtained, filled in the ointment tube, and sealed. Compared with the patch, the preparation process of the gel is simpler, and an appropriate amount of gel is extruded from the ointment tube and applied to the skin.
- the composition of the present invention provides a system which is relatively stable at high temperatures, and after storage for 10 days at 60 ° C, the relevant substance of the composition of the present invention is less than 4%, and the composition of the composition without the antioxidant is measured. More than 5%, the results are shown in Table 12 below. Table 12: Content of related substances in the composition of Example 5 The amount of the relevant substance-containing substance containing the relevant substance of the related substance in the composition 5-2 in the composition 5-2 of the composition 5-2 in the composition 5-2
- Example 6 Transdermal ointment containing rasagiline and antioxidants Table 13: Composition of transdermal ointment containing rasagiline and antioxidants Prescription
- Preparation method rasagiline and antioxidant components are added to the mixture of lanolin, liquid paraffin and petrolatum, milled to a fine paste and passed through a 100 mesh sieve, filled in an ointment tube, and sealed. When using, apply an appropriate amount of ointment from the ointment tube and apply it on the skin.
- the composition of the present invention provides a system which is relatively stable at high temperatures, and after 10 days of storage in an environment of 60 ° C, the composition of the composition of the present invention is found to be less than 3%, without the composition of the antioxidant. If the relevant substance is more than 5%, the relevant substance is less than 5%, and the system related substance without antioxidant is more than 5%. The results are shown in Table 14 below. Table 14: Content of related substances in the composition of Example 6
- Example 7 Transdermal cream containing rasagiline and antioxidant tocopherol
- Table 15 Composition of a composition containing a transdermal cream of rasagiline and an antioxidant tocopherol
- Preparation method the antioxidant tocopherol and the main drug rasagiline are added to the oil phase, heated to 80 ° C into a liquid state, added water phase, emulsifier and rasagiline, stirred, homogenized, after cooling As a cream. Fill in the ointment tube and seal. When using, apply a proper amount of cream from the ointment tube and apply it to the skin.
- the composition of the present invention provides a system which is relatively stable at high temperatures, and after storage at 60 ° C for 10 days, the related substances of the composition of the present invention having a substance of less than 5% and without the antioxidant are measured. More than 5%, the results are shown in Table 16. Table 16: Contents of related substances in the composition of Example 7
- Example 8 Transdermal cream containing rasagiline and antioxidant butyl hydroxy benzene
- Table 17 Composition of a composition containing a transdermal cream of rasagiline and an antioxidant butyl hydroxy benzene
- Preparation method Tocopherol and rasagiline are added to the oil phase, heated to 80 ° C to form a liquid, added with an aqueous phase, an emulsifier, stirred, homogenized, and allowed to form a cream after cooling. Fill in the paste tube and seal. When using, apply a proper amount of cream from the ointment tube and apply it to the skin.
- the composition of the present invention provides a system which is relatively stable at high temperatures, and after storage at 60 ° C for 10 days, the related substances of the composition of the present invention having a substance of less than 5% and without the antioxidant are measured. More than 5%, the results are shown in Table 18 below. Table 18: Contents of related substances in the composition of Example 8
- Example 9 Transdermal poultice containing rasagiline and antioxidant tocopherol
- Table 19 Formulation of a composition containing a transdermal patch of rasagiline and an antioxidant tocopherol
- Preparation method rasagiline is dissolved with azone and mixed with antioxidant, cross-linking agent and glycerin, and ground into a fine paste for use (A).
- the polymer carrier material is swollen in a part of water and then added with zinc oxide (prescription 9-1) or titanium dioxide (prescription 9-2; or kaolin and EDTA (prescription 9-3), milled into a paste form (B).
- Mix A and B grind, add tartaric acid (prescription 9-1) dissolved with the remaining water, and mash (prescription 9-2, 9-3) dissolved with the remaining water, and grind it into a paste.
- the composition of the present invention provides a system that is relatively stable at elevated temperatures, and the composition of the present invention is measured after storage at 60 ° C for 10 days.
- the relevant substance of the composition is less than 4%, and the related substance of the composition without the antioxidant is more than 5%. The results are shown in Table 20 below. Table 20: Contents of related substances in the composition of Example 9.
- Example 10 Transdermal poultice containing rasagiline and antioxidant butyl hydroxy benzene
- Table 21 Composition of a transdermal cataplasm containing rasagiline and an antioxidant butyl hydroxy benzene Prescription
- Preparation method rasagiline is dissolved with azone and mixed with antioxidant, cross-linking agent and glycerin, and ground into a fine paste for use (A).
- the polymer carrier material is swollen in some water and then added with zinc oxide (prescription 10-1) or titanium dioxide (prescription 10-2); or kaolin and EDTA (prescription 10-3), milled into a paste form (B) .
- composition of the present invention provides a system which is relatively stable at high temperatures, and after storage for 10 days at 60 ° C, the relevant substance of the composition of the present invention is less than 4%, and the composition of the composition without the antioxidant is measured. More than 5%, the results are shown in Table 22 below. Table 22: Content of related substances in the composition of Example 10
- Example 11 Membrane film containing rasagiline and antioxidant
- Table 23 Composition of a composition for a mucosal film containing rasagiline and an antioxidant
- Preparation method taking polyvinyl alcohol and adding appropriate amount of water to swell, and then heating and dissolving in a water bath to obtain polyvinyl alcohol cement, taking rasagiline, antioxidant, glycerin, Tween 80 dissolved in appropriate amount of water, adding to polyvinyl alcohol In the glue, mix the hook. Add distilled water to the specified amount, mix the hook, remove the bubbles, make the film, and dry it. When using, apply a certain size of the membrane to the oral mucosa.
- composition of the present invention provides a system that is relatively stable at high temperatures, and stores 10 at 60 ° C After the day, the relevant substance of the composition of the present invention was found to be less than 4%, and the related substance of the composition without the antioxidant was more than 5%, and the results are shown in Table 24 below.
- Example 12 Transdermal spray containing rasagiline and an antioxidant
- Table 25 Formulation of a composition containing a transdermal spray of rasagiline and an antioxidant
- Preparation method Take rasagiline and antioxidant and add ethanol to dissolve. Tween 80% is dissolved in water. Mix the two well and mix. When in use, the liquid will be sprayed on the surface of the skin.
- composition of the present invention provides a system which is relatively stable at high temperatures, and after storage at 60 ° C for 10 days, the related substances of the composition of the present invention having a substance of less than 5% and without the antioxidant are measured. More than 5%, the results are shown in Table 26 below.
- the pharmaceutical composition of the invention is not demanding in material selection, easy to obtain materials, and can also reduce production cost, and is easy to operate in industry.
- the invention has been described above by way of illustration. However, it should be understood that the present invention is by no means limited to these specific embodiments. A person skilled in the art can make various modifications or changes to the invention, and such modifications and variations are within the scope of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/504,178 US8859624B2 (en) | 2009-10-29 | 2010-10-28 | Stable rasagiline composition |
EP10826091.0A EP2494966B2 (en) | 2009-10-29 | 2010-10-28 | Stable composition of rasagiline |
JP2012535614A JP5936544B2 (ja) | 2009-10-29 | 2010-10-28 | 安定なラサギリン組成物 |
ES10826091.0T ES2504065T3 (es) | 2009-10-29 | 2010-10-28 | Composición estable de rasagilina |
AU2010312096A AU2010312096B2 (en) | 2009-10-29 | 2010-10-28 | Stable composition of rasagiline |
CA2777532A CA2777532C (en) | 2009-10-29 | 2010-10-28 | Stable rasagiline composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910191252.6 | 2009-10-29 | ||
CN200910191252.6A CN102048717B (zh) | 2009-10-29 | 2009-10-29 | 一种稳定的雷沙吉兰组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011050728A1 true WO2011050728A1 (zh) | 2011-05-05 |
Family
ID=43921343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/078189 WO2011050728A1 (zh) | 2009-10-29 | 2010-10-28 | 一种稳定的雷沙吉兰组合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8859624B2 (zh) |
EP (1) | EP2494966B2 (zh) |
JP (1) | JP5936544B2 (zh) |
CN (1) | CN102048717B (zh) |
AU (1) | AU2010312096B2 (zh) |
CA (1) | CA2777532C (zh) |
ES (1) | ES2504065T3 (zh) |
WO (1) | WO2011050728A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013035714A (ja) * | 2011-08-08 | 2013-02-21 | Japan Atomic Energy Agency | 高濃度かつ高放射能をもつテクネチウム−99m溶液の製造方法 |
JP2014534196A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−ホルミル−プロパルギル−アミノインダン |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
WO2013168032A1 (en) * | 2012-05-07 | 2013-11-14 | Micro Labs Limited | Pharmaceutical compositions comprising rasagiline |
CN103315983B (zh) * | 2012-12-20 | 2015-06-03 | 上海中西制药有限公司 | 一种雷沙吉兰制剂及其制备方法 |
CN104107210B (zh) * | 2014-05-21 | 2017-11-17 | 安徽康缘药业有限公司 | 一种抗疲劳微乳液及其制备方法 |
CN105496979B (zh) * | 2015-12-08 | 2018-06-05 | 重庆华森制药股份有限公司 | 一种雷沙吉兰片剂 |
CN114469902A (zh) * | 2020-10-23 | 2022-05-13 | 上海上药中西制药有限公司 | 雷沙吉兰或其药用盐舌下膜剂及其制备方法、应用 |
CN116036055A (zh) * | 2023-03-16 | 2023-05-02 | 上海世领制药有限公司 | 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1178461A (zh) * | 1995-03-02 | 1998-04-08 | R·P·舍雷尔有限公司 | 包括单胺氧化酶b抑制剂的药物组合物 |
CN1911211A (zh) * | 2006-08-25 | 2007-02-14 | 重庆医药工业研究院有限责任公司 | 雷沙吉兰口服固体制剂 |
CN101032474A (zh) | 2006-03-06 | 2007-09-12 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
CN101606923A (zh) | 2008-06-20 | 2009-12-23 | 重庆医药工业研究院有限责任公司 | 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) † | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
IL111240A (en) † | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
DE10060852A1 (de) * | 2000-12-06 | 2002-06-20 | Hexal Ag | Absorptionsmittel und Kanalbildner enthaltende wirkstoffundurchlässige Deckschicht oder abziehbare Schutzschicht eines transdermalen therapeutischen Systems |
US20040034083A1 (en) * | 2002-04-18 | 2004-02-19 | Stephenson Diane T. | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) |
AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
ES2551481T3 (es) * | 2006-02-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Uso de rasagilina para el tratamiento de atrofia multisistémica |
US20070287796A1 (en) * | 2006-06-12 | 2007-12-13 | General Electric Company | Method of stabilization of dihydric phenols |
CN100542524C (zh) † | 2006-09-29 | 2009-09-23 | 北京德众万全药物技术开发有限公司 | 一种含有雷沙吉兰的药用组合物 |
AU2007334428B2 (en) | 2006-12-14 | 2014-05-29 | Teva Pharmaceutical Industries, Ltd. | Crystalline solid rasagiline base |
US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
ES2389353T3 (es) | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Cápsulas de gelatina blanda de rasagilina |
NZ589547A (en) | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
CA2727021A1 (en) † | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
EP2343901B1 (en) | 2010-01-08 | 2017-11-29 | BlackBerry Limited | Method and device for video encoding using predicted residuals |
US10648184B2 (en) † | 2017-09-22 | 2020-05-12 | E-Z Bead, Llc | Stop bead for panel-based siding, and related methods and systems |
-
2009
- 2009-10-29 CN CN200910191252.6A patent/CN102048717B/zh active Active
-
2010
- 2010-10-28 JP JP2012535614A patent/JP5936544B2/ja active Active
- 2010-10-28 CA CA2777532A patent/CA2777532C/en active Active
- 2010-10-28 EP EP10826091.0A patent/EP2494966B2/en active Active
- 2010-10-28 ES ES10826091.0T patent/ES2504065T3/es active Active
- 2010-10-28 WO PCT/CN2010/078189 patent/WO2011050728A1/zh active Application Filing
- 2010-10-28 US US13/504,178 patent/US8859624B2/en active Active
- 2010-10-28 AU AU2010312096A patent/AU2010312096B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1178461A (zh) * | 1995-03-02 | 1998-04-08 | R·P·舍雷尔有限公司 | 包括单胺氧化酶b抑制剂的药物组合物 |
CN101032474A (zh) | 2006-03-06 | 2007-09-12 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
CN1911211A (zh) * | 2006-08-25 | 2007-02-14 | 重庆医药工业研究院有限责任公司 | 雷沙吉兰口服固体制剂 |
CN101606923A (zh) | 2008-06-20 | 2009-12-23 | 重庆医药工业研究院有限责任公司 | 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2494966A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013035714A (ja) * | 2011-08-08 | 2013-02-21 | Japan Atomic Energy Agency | 高濃度かつ高放射能をもつテクネチウム−99m溶液の製造方法 |
JP2014534196A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | R(+)−n−ホルミル−プロパルギル−アミノインダン |
EP2766002A4 (en) * | 2011-10-10 | 2015-07-01 | Teva Pharma | R (+) - N-formyl-propargyl-aminoindan |
Also Published As
Publication number | Publication date |
---|---|
EP2494966B2 (en) | 2020-11-11 |
CN102048717B (zh) | 2014-02-19 |
AU2010312096A1 (en) | 2012-05-17 |
CN102048717A (zh) | 2011-05-11 |
JP5936544B2 (ja) | 2016-06-22 |
US20120214877A1 (en) | 2012-08-23 |
ES2504065T3 (es) | 2014-10-08 |
US8859624B2 (en) | 2014-10-14 |
EP2494966A4 (en) | 2013-03-06 |
AU2010312096B2 (en) | 2013-10-31 |
EP2494966B1 (en) | 2014-07-02 |
EP2494966A1 (en) | 2012-09-05 |
CA2777532C (en) | 2014-09-16 |
JP2013509359A (ja) | 2013-03-14 |
CA2777532A1 (en) | 2011-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011050728A1 (zh) | 一种稳定的雷沙吉兰组合物 | |
JP5564469B2 (ja) | ロチゴチン投与のための改善された経皮送達系 | |
US8246980B2 (en) | Transdermal delivery system | |
BR112015011729B1 (pt) | Sistema terapêutico transdérmico, kit compreendendo o mesmo e método para a preparação do mesmo | |
PT1490052E (pt) | Dispositivo para administração transdérmica da base da rotigotina. | |
JPS61155321A (ja) | 経皮貼剤及びその製造方法 | |
NO334187B1 (no) | Forbedret transdermalt leveringssystem | |
CN106604748A (zh) | 具有改进的稳定性的含有罗替戈汀的经皮吸收制剂 | |
EP1613584B1 (de) | Pharmazeutische formulierungen enthaltend hochreine basen von 3,3-diphenylpropylaminmonoestern | |
EP2650019B1 (en) | Noradrenergic and specific serotonergic antidepressant-containing transdermal patch | |
WO2021098791A1 (zh) | 一种含有美金刚的透皮贴剂 | |
KR20070059079A (ko) | 경피 페로스피론 투여용 의약적 조성물 | |
JP2002516879A (ja) | 非ステロイド性消炎鎮痛剤の経皮投与用組成物 | |
CN115475152A (zh) | 氟比洛芬的外用制剂及其制备方法 | |
DE10315878A1 (de) | Transdermale Verabreichung von (R)-3,3-Diphenylpropylamin-Monoestern | |
KR101680801B1 (ko) | 피부자극이 완화된 경피흡수제제 | |
JP2003160489A (ja) | オンダンセトロン経皮吸収用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10826091 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2777532 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010312096 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012535614 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13504178 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010826091 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010312096 Country of ref document: AU Date of ref document: 20101028 Kind code of ref document: A |